Advertisement

Issues in Opioid Therapy for the Treatment of Cancer Pain

  • K. M. Foley
Part of the Developments in Critical Care Medicine and Anesthesiology book series (DCCA, volume 29)

Abstract

Evaluation and treatment of pain in the patient with cancer has now evolved to encompass a series of clinical guidelines which define a comprehensive approach to the management of this difficult medical problem. Current knowledge in cancer pain includes the description of the common cancer pain syndromes in this population, as well as their postulated neurophysiologic mechanisms; a classification of the types of patients with pain, the different types of pain (acute, chronic, breakthrough) and the psychological factors that contribute to and alter the pain complaint; the development and implementation of well-validated pain measurement methodologies to assess pain intensity, degree of relief, and mood (psychological distress); the modeling of pharmacokinetic pharmacodynamic relationships to correlate opioid drug distribution with pain relief and side-effects; and refined use of anesthetic and neurosurgical approaches and the broader integration of cognitive-behavioral approaches (1–16).

Keywords

Neuropathic Pain Cancer Pain Opioid Drug Cancer Pain Management Chronic Cancer Pain 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Cancer Pain Relief. World Health Organization, Geneva, 1986.Google Scholar
  2. 2.
    Cancer Pain Relief and Palliative Care, World Health Organization, Geneva, 1990.Google Scholar
  3. 3.
    Bonica JJ: Cancer pain, The Management of Pain, JJ Bonica (ed). Philadelphia, Lea & Febiger, 400–434, 1990Google Scholar
  4. 4.
    Foley KM: The treatment of cancer pain. N Engl J Med 313: 84–95, 1985PubMedCrossRefGoogle Scholar
  5. 5.
    Elliott K, Foley KM: Neurologic pain syndromes in patients with cancer. Neurologic Clinics, Pain: Mechanisms and Syndromes, Vol. 7, Portenoy RK (ed). WB Saunders, Philadelphia, 1989, pp. 333–360Google Scholar
  6. 6.
    Portenoy RK: Cancer pain: pathophysiology and syndromes. Lancet 339: 1026–1031, 1992PubMedCrossRefGoogle Scholar
  7. 7.
    Portenoy RK, Hagen NA: Breakthrough pain: definition and management. Oncology 3(Suppl): 25–29, 1989PubMedGoogle Scholar
  8. 8.
    Ahles TA, Blanchard EB, Ruckdeschel JC: The multidimensional nature of cancer related pain. Pain 17: 277–289, 1983PubMedCrossRefGoogle Scholar
  9. 9.
    Breitbart WS, Holland J: Psychiatric aspects of cancer pain, Advances in Pain Research and Therapy, Vol. 16. Foley KM, Bonica JJ, Ventafridda V (eds). Proceedings of the Second International Congress on Cancer Pain. Raven Press, New York, 1990, pp. 73–88Google Scholar
  10. 10.
    Fishman B, Pasternak S, Wallenstein SL, et al: The Memorial Pain Assessment Card: a valid instrument for the evaluation of cancer pain. Cancer 60: 1151–1158, 1987PubMedCrossRefGoogle Scholar
  11. 11.
    Daut RL, Cleeland CS, Flanery RC: The development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases. Pain 17: 197–210, 1983PubMedCrossRefGoogle Scholar
  12. 12.
    Graham C, Bond SS, Gertrovitch MM, Cook MR: Use of the McGill Pain Questionnaire in the management of cancer pain—replicability and consistency. Pain 8: 377–387, 1980PubMedCrossRefGoogle Scholar
  13. 13.
    Inturrisi CE, Colburn WA, Kaiko RF, Houde RW, Foley KM: Pharmacokinetic and pharmacodynamics of methadone in patients with chronic pain. Clin Pharmacology & Therapeutics 41: 392–401, 1987CrossRefGoogle Scholar
  14. 14.
    Hill HF, Chapman CR, Saeger LS, Bjurstrom R, Walter MH, Schoene RB, Kippes M: Steady-state infusions of opioids in humans: II. Concentration-effect relationships and therapeutic margins. Pain 43: 69–80, 1991CrossRefGoogle Scholar
  15. 15.
    Cousins MJ: Anesthetic approaches in cancer pain, Advances in Pain Research and Therapy, Vol 16. Foley KM, Ventafridda V, Bonica JJ (eds). Second International Congress on Cancer Pain. New York, Raven Press, 1990, pp. 249–274Google Scholar
  16. 16.
    Arbit E: Neurosurgical management of cancer pain, Advances in Pain Research and Therapy, Vol 16. Foley KM, Ventafridda V, Bonica JJ (eds). Second International Congress on Cancer Pain. New York, Raven Press, 1990, pp. 289–300Google Scholar
  17. 17.
    Foley KM: Controversies in cancer pain—medical perspective. Cancer 63: 2257–2266, 1989PubMedCrossRefGoogle Scholar
  18. 18.
    Portenoy RK, Foley KM, Inturrisi CE: The nature of opioid responsiveness and its implications for neuropathic pain: new hypotheses derived from studies of opioid infusions. Pain 43: 273–286, 1990PubMedCrossRefGoogle Scholar
  19. 19.
    Foley KM: Clinical tolerance to opioids, Towards a New Pharmacotherapy of Pain. Dahlem Konferenzen. Basbaum AI, Besson JM (eds). Chichester: John Wiley & Son, 1991, pp. 181–204Google Scholar
  20. 20.
    Foley KM: Pain syndromes in patients with cancer, Advances in Pain Research and Therapy, Vol. 2. Bonica JJ, Ventafridda V (eds), New York, Raven Press, 1979, pp. 59–75Google Scholar
  21. 21.
    Daut RL, Cleeland CS: The prevalence and severity of pain in cancer. Cancer 50: 1913–1918, 1982PubMedCrossRefGoogle Scholar
  22. 22.
    Spiegel D, Bloom JR: Pain in metastatic breast cancer. Cancer 52: 341–345, 1983PubMedCrossRefGoogle Scholar
  23. 23.
    Ventafridda V, Tamburini M, Caraceni A, DeConno F, Naldi F: A validation study of the WHO method for cancer pain relief. Cancer 59: 850–856, 1987PubMedCrossRefGoogle Scholar
  24. 24.
    Stjernsward J: WHO cancer pain relief programme. Cancer Surv 7: 195–208, 1988PubMedGoogle Scholar
  25. 25.
    Cleeland CS: Pain control: public and physician attitudes, Advances in Pain Research and Therapy, Vol-11. Hill CS Fields WS (eds). Raven Press, New York 1989, pp. 81–89Google Scholar
  26. 26.
    Weissman DE, Dahl JL: Attitudes about cancer pain: A survey of Wisconsin’s first year medical students. J Pain Symptom Manage 5: 345–349, 1990PubMedCrossRefGoogle Scholar
  27. 27.
    Van Roenn JH, Cleeland CS, Gonin R, Hatfield A, Pandya KJ: Physician’ attitudes toward cancer pain management survey: results of the Eastern Cooperative Oncology Group Survey. Ann Int Med In press, 1993Google Scholar
  28. 28.
    Ferell B, McGuire DB, Donovan MI: Knowledge and beliefs regarding pain in a sample of nursing faculty. J Prof Nurs In press, 1993Google Scholar
  29. 29.
    Joranson DE, Cleeland CS, Weissman DE, Gilson AM: Cancer pain, opioids and the law: a survey of state medical board members. Fed Bulletin: The Medical Journal of Licensure and Discipline In press, 1993Google Scholar
  30. 30.
    Peteet J, Tay V, Cohen G, Macintyre J: Pain characteristics and treatment in an outpatient cancer population. Cancer 57: 1259–1265, 1986PubMedCrossRefGoogle Scholar
  31. 31.
    Grossman SA, Sheidler VR, Swedeen K, Mucenski J, Pianladosi S: Correlation of patient and care giver ratings of cancer pain. J Pain Symptom Manage 6: 53–57, 1991PubMedCrossRefGoogle Scholar
  32. 32.
    McDonald N: Initiatives in China, WHO News. Palliative Medicine 6: 6–8, 1992CrossRefGoogle Scholar
  33. 33.
    Takeda F: Changing attitudes toward narcotic use in cancer pain management in Japan. Postgrad Med J S31–34, 1992Google Scholar
  34. 34.
    Report of the International Narcotics Control Board for 1989. Demands for and Supply of Opiates for Medical and Scientific Needs. United Nations, New York, 1989Google Scholar
  35. 35.
    Dahl JL, Joranson DE: The Wisconsin Cancer Pain Initiative, Advances in Pain Research and Therapy, Vol. 16. Foley KM, Ventafridda V, Bonica JJ (eds). Second International Congress on Cancer Pain. New York, Raven Press, 1990, pp. 499–503Google Scholar
  36. 36.
    Ventafridda V, Tamburini M, DeConno F: Comprehensive treatment of cancer pain, Advances in Pain Research and Therapy, Vol. 9. Fields HL, Dubner R, Cervero F (eds). Raven Press, Ltd. New York 617–628, 1985Google Scholar
  37. 37.
    Ventafridda V, DeConno F, Ripamonti C, Gamba A, Tamburini M: Quality-of-life assessment during a palliative care programme. Annals of Oncology 1: 415–420, 1990PubMedGoogle Scholar
  38. 38.
    Scott JF: Palliative Care 2000: What’s Stopping Us? J Pall Care 8: 5–8, 1992Google Scholar
  39. 39.
    Committee on Quality Assurance Standards: American Pain Society quality assurance standards for relief of acute pain and cancer pain. Proceedings of VIth World Congress on Pain. Bond MR, Charlton JE, Woolf CJ (eds). Amsterdam, Elsevier 1991, 185–189Google Scholar
  40. 40.
    Arner S, Meyerson BA: Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain. Pain 33: 11–23, 1988PubMedCrossRefGoogle Scholar
  41. 41.
    Hanks GW, Justins DM: Cancer pain management. Lancet 339: 1031–1035, 1992PubMedCrossRefGoogle Scholar
  42. 42.
    Cherny NI, Thaler HT, Friedlander-Klar H, Lapin J, Portenoy RK: Opioid responsiveness of neuropathic cancer pain: combined analysis of single dose analgesic trials. Proc ASCO 11: 383, 1992Google Scholar
  43. 43.
    Portenoy RK, Foley KM, Inturrisi CE: The nature of opioid responsiveness and its implications for neuropathic pain: new hypotheses derived from studies of opioid infusions. Pain 43: 273–286, 1990PubMedCrossRefGoogle Scholar
  44. 44.
    Foley KM: The role of opioid analgesics in neuropathic pain, Lesions of the primary afferent fibers as a tool for the study of clinical pain Besson JM, Guilbaud G (eds). Amsterdam, Elsevier Science Publ 1991, pp. 277–292Google Scholar
  45. 45.
    Rowbotham MC, Fields HL: Post-herpetic neuralgia: the relation of pain complaint, sensory disturbance, and skin temperature. Pain 39: 129–144, 1989PubMedCrossRefGoogle Scholar
  46. 46.
    Galer BS, Coyle N, Pasternak GW, Portenoy RK: Individual variability in the response to different opioids: report of five cases. Pain 49: 87–91, 1992PubMedCrossRefGoogle Scholar
  47. 47.
    Portenoy RK: Issues in the management of neuropathic pain, Towards a New Pharmacotherapy of Pain. Basbaum A, Besson J-M (eds). New York, John Wiley & Sons, 1991, pp. 393–416Google Scholar
  48. 48.
    Macaluso C, Foley KM: Adjuvant analgesic drugs in cancer pain management, Relief of Chronic Pain. Aronoff GM (ed). Addison Wesley Pubs. Boston, Mass., In Press, 1992Google Scholar
  49. 49.
    Sawe J: Morphine and its 3-and 6-glucuronides in plasma and urine during chronic oral administration in cancer patients, Advances in Pain Research and Therapy, Vol. 8. Foley KM, Inturrisi CE (eds). Raven Press, New York 1986, pp. 45–55Google Scholar
  50. 50.
    Osborne RJ, Joel SP, Slevin ML: Morphine intoxication in renal failure: the role of morphine-6-glucuronide. Br Med J 292: 1548–1549, 1986CrossRefGoogle Scholar
  51. 51.
    Osborne RJ, Joel SP, Trew D, Slevin ML: The analgesic activity of morphine-6-glucuronide. Lancet I: 828, 1988CrossRefGoogle Scholar
  52. 52.
    Osborne RJ, Joel SP, Trew D, Slevin ML: Morphine and metabolite behavior after different routes of morphine administration: demonstration of the importance of the active metabolite morphine-6-glucuronide. Clin Pharmacol Ther 47: 12–19, 1990PubMedCrossRefGoogle Scholar
  53. 53.
    Shimomura K, Kamata O, Ueki S, et al: Analgesic effect of morphine glucuronides, Tohoku J Exp Med 105: 45–52, 1971PubMedCrossRefGoogle Scholar
  54. 54.
    Pasternak GW, Bodnar RJ, Clark JA, Inturrisi CE: Morphine-6-glucuronide, a potent mu agonist. Life Sci 41: 2845–2849, 1987PubMedCrossRefGoogle Scholar
  55. 55.
    Paul D, Standifer KM, Inturrisi CE, Pasternak GW: Pharmacological characterization of morphine-6-glucuronide, a very potent morphine metabolite. J Pharmacol Exp Ther 251: 477–483, 1989PubMedGoogle Scholar
  56. 56.
    Poulain P, Moran-Ribon A, Hanks GW, Hoskin PJ, Aherne GW, Chapman DP. CSF concentrations of morphine-6-glucuronide after oral administration of morphine. Pain 5 (Suppl): S194, 1990CrossRefGoogle Scholar
  57. 57.
    Hand CW, Blunnie WP, Claffey LP, et al: Potential analgesic contribution from morphine-6-glucuronide in CSF Lancet II: 1207–1208, 1987Google Scholar
  58. 58.
    Portenoy RK, Thaler HT, Inturrisi CE, Friedlander-Klar H, Foley KM: The metabolite, morphine-6-glucuronide, contributes to the analgesia produced by morphine infusion in pain patients with normal renal function. Clin Pharm Ther 51: 422–431, 1992CrossRefGoogle Scholar
  59. 59.
    Portenoy RK, Khan E, Layman M, Lapin J, Malkin MG, Foley KM, Cerbone DJ, Inturrisi CE: Chronic morphine therapy for cancer pain: Plasma and cerebrospinal fluid morphine and morphine-6-glucuronide concentrations. Neurology 41: 1457–1461, 1991PubMedCrossRefGoogle Scholar
  60. 60.
    Portenoy RK, Foley KM, Stulman J, Khan E, Adelhardt J, Layman Cerbone DF, Inturrisi CE: Plasma morphine and morphine-6-glucuronide during chronic morphine therapy for cancer pain: plasma profiles, steady-state concentrations and the consequences of renal failure: Pain 47: 13–19, 1991PubMedCrossRefGoogle Scholar
  61. 61.
    Petreson GM, Randall CTC, Paterson J: Plasma levels of morphine and morphine glucuronides in the treatment of cancer pain: relationship to renal function and route of administration. Eur J Clin Pharmacol 38: 121–124, 1990Google Scholar
  62. 62.
    Hagen N, Foley KM, Cebrone DJ, Portenoy RK, Inturrisi CE: Chronic nausea and morphine-6-glucuronide. J Pain Symptom Manage 6: 125–128, 1991PubMedCrossRefGoogle Scholar
  63. 63.
    McQuay HJ, Caroll D, Faura CC, Gavaghan DJ, Hand CW, Moore RA: Oral morphine in cancer pain: influences on morphine and metabolite concentration. Clin Pharmacol Ther 48: 236–244, 1990PubMedCrossRefGoogle Scholar
  64. 64.
    Breda M, Bianchi M, Ripamonti C, Zecca E, Ventafridda V, Panerai AE: Plasma morphine and morphine-6-glucuronide patterns in cancer patients after oral, subcutaneous, sublingual, and rectal short-term administration. Int J Clin Pharmacol Res 11: 93–97, 1991PubMedGoogle Scholar
  65. 65.
    Fainsinger R, Schoellrs T, and Bruera E: Methadone in the management of cancer pain: a review. Pain 52: 137–147, 1993PubMedCrossRefGoogle Scholar
  66. 66.
    Grochow L, Sheidler V, Grossman S, et al: Does intravenous methadone provide longer lasting analgesia than intravenous morphine? A randomized double-blind study. Pain 38: 151–157, 1989PubMedCrossRefGoogle Scholar
  67. 67.
    Inturrisi CE, Colburn WA, Kaiko RF, Houde RW, Foley KM. Pharmacokinetic and pharmacodynamics of methadone in chronic pain patients. Clin Pharmacology & Therapeutics, 41: 392–401, 1987CrossRefGoogle Scholar
  68. 68.
    Ettinger DS, Vitale PJ, Trump DL: Important clinical pharmacologic considerations in the use of methadone in cancer patients. Cancer Treat Rep 63: 457–459, 1979PubMedGoogle Scholar
  69. 69.
    Rogers AG: The use of methadone in opioid tolerant patients. J Pain Symptom Manage 3: 45, 1988PubMedCrossRefGoogle Scholar
  70. 70.
    Kalso E, Poyhia R, Onnela P, Lanko K, Tigersledt I, Tammusto T: Intravenous morphine and oxycodone for pain after abdominal surgery. ACTA Anaesthesiol Scand 35: 642–646, 1991PubMedCrossRefGoogle Scholar
  71. 71.
    Poyhia R, Olkkola KT, Seppala T, Kalso E: The pharmacokinetics of oxycodone after intravenous injection in adults. Br J Clin Pharmac 32: 516–518, 1991CrossRefGoogle Scholar
  72. 72.
    Poyhia R, Seppala T, Olkkola KT, Kalso E: The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. Br J Clin Pharma 33: 617–621, 1992CrossRefGoogle Scholar
  73. 73.
    Rogers A: The under utilization of oxycodone. J Pain Symptom Manage 6: 452, 1991PubMedCrossRefGoogle Scholar
  74. 74.
    Moulin DE, Kreeft JH, Murray-Parsons N, Bouquillon AL: Comparison of continuous subcutaneous and intravenous hydromorphone infusions for management of cancer pain. Lancet 337: 465–468, 1991PubMedCrossRefGoogle Scholar
  75. 75.
    Babul N, Darke AC: Palliative role of hydromorphone metabolites in myoclonus. Pain 51: 260–261, 1992PubMedCrossRefGoogle Scholar
  76. 76.
    Moulin DE, Ling GSF, Pasternak GW: Unidirectional analgesic cross-tolerance between morphine and levorphanol in the rat. Pain 33: 233–239, 1988PubMedCrossRefGoogle Scholar
  77. 77.
    Kaiko RF, Foley KM, Grabinski PY, et al: Central nervous system excitatory effects of meperidine in cancer patients. Ann Neurol 131: 180–185, 1985Google Scholar
  78. 78.
    Portenoy RK, Southam MA, Gupta SK, Lapin J, Layman M, Inturrisi CE, Foley KM: Transdermal fentanyl for cancer pain: repeated dose pharmacokinetics. Anesthesiology 78: 36–43, 1993PubMedCrossRefGoogle Scholar
  79. 79.
    Coyle N, Adelhardt J, Foley KM, Portenoy RK: Character of terminal illness in the advanced cancer patient: pain and other symptoms in the last 4 weeks of life. J Pain Symptom Manage 5: 83–93, 1990PubMedCrossRefGoogle Scholar
  80. 80.
    Mather LE. Novel methods of analgesic drug delivery, Proceedings of the Vlth World Congress on Pain. Bond MR, Charlton JEO, Woolf CJ (eds). Amsterdam, Elsevier 159–174, 1990Google Scholar
  81. 81.
    McQuay HJ: The logic of alternative routes. J Pain Symptom Manage 5: 73–136, 1991Google Scholar
  82. 82.
    Twycross RG: Clinical experience with diamorphine in advanced malignant disease. Int J Clin Pharm 9: 184–198, 1974Google Scholar
  83. 83.
    Portenoy RK, Moulin DE, Rogers AG, Inturrisi CE, Foley KM. Continuous intravenous infusion of opioids in cancer pain: Review of 46 cases and guidelines for use. Cancer Treat Rep 7: 575–581, 1986Google Scholar
  84. 84.
    Kanner RM, Foley KM. Patterns of narcotic drug use in a cancer pain clinic. Research developments in drug and alcohol use. Ann NY Acad Sci 362: 161–172, 1981PubMedCrossRefGoogle Scholar
  85. 85.
    Moulin DE, Max MB, Kaiko RF, Inturrisi CE, Maggard J, Yaksh T, Foley KM: The analgesic efficacy of intrathecal D-Ala2-D-Leu5-enkephalin in cancer patients with chronic pain. Pain 23: 213–221, 1985PubMedCrossRefGoogle Scholar
  86. 86.
    Foley KM: Clinical tolerance to opioids, Toward a New Pharmacotherapy of Pain. Dahlem Konferenzen. Basbaum AI, Besson JM (eds). Chichester, John Wiley & Sons, 181–204, 1991Google Scholar
  87. 87.
    Foley KM: Changing concepts of tolerance to opioids. What the cancer patient has taught us, Current & Emerging Issues in Cancer Pain: Research & Practice. Chapman CR, Foley KM (eds). New York, Raven Press, pp. 331–349, 1993Google Scholar
  88. 88.
    Houde RW, Wallenstein SL, Beaver WT: Evaluation of analgesics in patients with cancer pain, Clinical Pharmacology. Section 6, Vol. 1. International Encyclopedia of Pharmacology and Therapeutics. Lasagna L (ed). Oxford, Pergamon 1966, pp. 9–98Google Scholar
  89. 89.
    Trujillo KA, Akil H: Opiate tolerance and dependence: recent findings and synthesis. The New Biologist 3: 915–923, 1991PubMedGoogle Scholar
  90. 90.
    Trujillo KA, Akil H: MK801 prevents the development of opioid tolerance. Science 251: 85–88, 1991PubMedCrossRefGoogle Scholar
  91. 91.
    Marek P, Ben-Eliyahu S, Gold M, Liebeskind JC: Excitatory amino acid antagonists (kynurenic acid and MK-801) attenuate the development of morphine tolerance in the rat. Brain Research 547: 77–81, 1991PubMedCrossRefGoogle Scholar
  92. 92.
    Breitbart W: Cancer pain and suicide. Advances in Pain Research and Therapy, Vol 16. Second International Congress on Cancer Pain, Foley KM, Ventafridda V, Bonica J (eds). New York, Raven Press, 399–412, 1990Google Scholar
  93. 93.
    Foley KM: The relationship of pain & symptom management to patient requests for physician-assisted suicide. J Pain Symptom Manage 6: 289–297, 1991PubMedCrossRefGoogle Scholar
  94. 94.
    Ventafridda V, Ripamonti C, DeConno F, Tamburini M: Symptom prevalence and control during cancer patients’ last days of life. J Palliative Care 6: 7–11, 1990Google Scholar
  95. 95.
    Roy DJ; Need they die before they sleep? J Palliative Care 6: 3–4, 1990Google Scholar
  96. 96.
    Mount B: A final crescendo of pain? J Palliative Care 6: 5–6, 1990Google Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1994

Authors and Affiliations

  • K. M. Foley

There are no affiliations available

Personalised recommendations